Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;99(6):592-603.
doi: 10.1111/aos.14697. Epub 2020 Dec 16.

Insights into multiple sclerosis-associated uveitis: a scoping review

Pauline Casselman  1 , Cathérine Cassiman  2 , Ingele Casteels  2 , Pieter-Paul Schauwvlieghe  2
Affiliations
Free article

Insights into multiple sclerosis-associated uveitis: a scoping review

Pauline Casselman et al. Acta Ophthalmol. 2021 Sep.
Free article

Abstract

Purpose: This paper is a scoping review of research on multiple sclerosis (MS)-associated uveitis to determine its epidemiology, pathophysiology, clinical features and treatment.

Methods: A comprehensive search of the medical databases MEDLINE (PubMed), EMBASE, Web of Science and Cochrane was carried out on 25 November 2019, to identify papers published between 1980 and 2019 that focus on patients with MS-associated uveitis.

Results: Based on large cohort studies (n ≥ 1000), the prevalence of uveitis in patients with MS is estimated to be 0.53-1.34% (mean = 0.83%), and MS is diagnosed in 0.52-3.20% (mean = 1.30%) of patients with uveitis. The condition is most frequent among middle-aged women. Patients usually complain of floaters and/or blurred vision, with bilateral intermediate uveitis (with retinal vasculitis) as the most frequent ophthalmological finding. Both MS and intermediate uveitis are associated with HLA-DRB1*15:01 and IL-2RA gene polymorphism rs2104286 A > G, suggesting a common genetic background. T cells, and possibly B cells, play an important role in both autoimmune disorders. Multiple sclerosis (MS)-related uveitis is classically treated as non-infectious uveitis, with corticosteroids as the first treatment step. Other treatments include immunosuppressants, cryotherapy, laser photocoagulation and vitrectomy. These treatment options have a limited, if any, effect on the course of MS and can be complicated by side-effects. As treatment strategies for MS have increased in the last decade, it would be interesting to evaluate the efficacy of these new treatments during the course of uveitis. Moreover, the correlation between retinal periphlebitis and MS could be established more accurately with the recently developed techniques of wide-field fluorescein angiography in a large cohort of MS patients.

Conclusion: MS-associated uveitis is a rare, highly discussed pathology about which much is still unknown. Large epidemiological studies and extrapolation of new MS treatments to this condition are warranted.

Keywords: autoimmune disease; multiple sclerosis; scoping review; uveitis.

PubMed Disclaimer

References

    1. Abd El Latif E, Abdelhalim AS, Montasser AS et al. (2020): Pattern of intermediate uveitis in an Egyptian cohort. Ocul Immunol Inflamm 28: 524-531.
    1. Abu El-Asrar AM, Herbort CP & Tabbara KF (2005): Retinal vasculitis. Ocul Immunol Inflamm 13: 415-433.
    1. Acharya NR, Tham VM, Esterberg E, Borkar DS, Parker JV, Vinoya AC & Uchida A (2013): Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study. JAMA Ophthalmol 131: 1405-1412.
    1. Arnold AC, Pepose JS, Hepler RS & Foos RY (1984): Retinal periphlebitis and retinitis in multiple sclerosis. I. Pathologic characteristics. Ophthalmology 91: 255-262.
    1. Babu BM & Rathinam SR (2010): Intermediate uveitis. Indian J Ophthalmol 58: 21-27.

Publication types